IPCA Labs(Weekly): Critical Confluence at 50/100-WMA Support

245
IPCA Laboratories is currently testing a significant structural inflection point on the weekly timeframe. Price action is hovering at the convergence of the 50-Week and 100-Week Moving Averages (1,420 - 1,450 range). The resolution of this test will dictate the primary trend for the medium term, presenting two distinct, actionable scenarios.

Technical Context:
The 50-WMA and 100-WMA historically act as heavy dynamic support during primary uptrends. The stock is currently compressing at this confluence, requiring a definitive weekly close to confirm directional bias.

Scenario A: Bullish Continuation (Support Defended)
If buyers successfully defend this moving average confluence, the primary uptrend remains intact, setting up a continuation trade.
  • Thesis: Support holds, initiating a new impulsive wave upward.
  • Trigger: A strong, bullish weekly close above the 50-WMA and 100-WMA confluence.
  • Targets: Retest of structural resistance at 1,624 (Point X), followed by the All-Time High at 1,755.
  • Invalidation (SL): A close slightly below the 100-WMA or the recent structural swing low.

Scenario B: Bearish WXY Correction (Support Fails)
A breakdown below this major support confluence signals structural weakness and opens the door for a deeper macro correction.
  • Thesis: Failure to hold the 50/100-WMA confluence initiates a WXY double combo correction.
  • Trigger: A decisive weekly close below both the 50-WMA and 100-WMA.
  • Targets: Initial downside target at 1,168 (Wave W low). A sustained break below this level exposes the 1.0 Fibonacci extension at 1,036, which aligns with the deeper 200-WMA.
  • Invalidation (SL): A close back above the 50-WMA.

Summary:
Directional bias is currently neutral pending a weekly close. Market participants should wait for candle confirmation to dictate entry and adhere strictly to defined invalidation levels to manage downside risk.

Disclaimer: Pleae DYOR. Not a buy/sell recommendation. Educational only.

免責聲明

這些資訊和出版物並非旨在提供,也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。